Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) have been considered the gold standard for the management of CNV secondary to AMD but also secondary to other macular diseases where currently four medications have been widely and effectively used in clinical practice: ranibizumab, bevacizumab, aflibercept, and brolucizumab [26]. This evidence concerns the gene VEGFA and age-related macular degeneration.